Poor treatment tolerance in head and neck cancer patients with low muscle massMarco A. Mascarella, Shaum Sridharan, Katie Traylor et al.|Head & Neck|2022Cited by 20
Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival BenefitMarco A. Mascarella, Umamaheswar Duvvuri, Tolani F. Olonisakin et al.|Clinical Cancer Research|2023Cited by 10
Predicting short-term treatment toxicity in head and neck cancer through a systematic review and meta-analysisMarco A. Mascarella, Marie‐Jeanne Kergoat, Varun Vendra et al.|Journal of Geriatric Oncology|2024Cited by 9
Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma.Marco A. Mascarella, Umamaheswar Duvvuri, Varun Vendra et al.|Journal of Clinical Oncology|2021Cited by 3